Company Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions.
Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.
Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers.
The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
| Country | MA |
| Founded | 2013 |
| IPO Date | Oct 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
Contact Details
Address: 200 Arsenal Yards Blvd., Ste. 210 Watertown, Massachusetts 02472 United States | |
| Phone | 617-898-8824 |
Stock Details
| Ticker Symbol | SQZB |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001604477 |
| Employer ID | 46-2431115 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Howard Bernstein M.D., Ph.D. | Interim Chief Executive Officer and Director |
| Lawrence J. Knopf Esq. | General Counsel and Secretary |
| Dr. Marshelle Smith Warren M.D. | Chief Medical Officer |
| Dr. Robert S. Langer Jr., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Richard V. Capasso CPA | Chief Accounting Officer |
| David First | Chief People Officer |
| Ipsita Roymoulik Ph.D. | Senior Vice President of CMC and QUALITY |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 23, 2024 | DEFM14A | Filing |
| Jan 12, 2024 | PREM14A | Filing |
| Jan 4, 2024 | 15-12G | Securities registration termination |
| Dec 22, 2023 | 8-K | Current Report |
| Dec 1, 2023 | EFFECT | Notice of Effectiveness |
| Nov 30, 2023 | POS AM | Post-Effective amendments for registration statement |
| Nov 30, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 8, 2023 | 10-Q | Quarterly Report |